We are in the early stages of applying technology solutions to cognitive and behavioral issues. Ranging from attention deficit to depression, we are excited to support emerging players who will address these important conditions and grow the behavioral health market.
We are moving away from a “one-size-fits-all” mentality of treating and managing diseases to a more personalized definition of health. Integrating insights from genomics and other omics technologies, clinical records, behavioral data, and social interactions allow us to tailor treatment and prevention to each individual patient.
We are capturing vast amounts of healthcare data on both individuals and populations. We want to place big bets on solutions that can generate meaningful data, intelligently analyze and demonstrate competitive insights to improve patient and population outcomes.
Evidence-based and clinically validated digital interventions can improve outcomes for patients by managing or preventing a disease, optimizing medication, or directly treating a disease. We foresee a future where software will be routinely prescribed to treat patients with acute and chronic conditions.
We are only now beginning to understand the significance of the trillions of microorganisms associated with the human body, and their impact on human health. We are bullish on novel technologies that leverage the microbiome’s genetic diversity to develop new diagnostics or therapeutics to improve management of diseases.
Rapid technical and scientific advancements have given us the ability to develop novel diagnostics and innovative treatments that were not possible only a few years ago. We seek to invest in companies and individuals looking to make this future a reality (e.g. VR/AR, neurotech, blockchain).